Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT.
Yi-Shan YeMyriam LabopinJia ChenDe-Pei WuTobias Gedde-DahlDidier BlaiseGerard SocièEdouard ForcadeUrpu SalmenniemiSébastien MauryJurjen VersluisAli BazarbachiArnon NaglerEolia BrissotLin LiYi LuoJimin ShiFabio CiceriHe HuangFlorent MalardNorbert-Claude GorinPublished in: Blood cancer journal (2024)